Blocking fatty ceramides could stop acute kidney injury—and possibly revolutionize mitochondrial disease treatment.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi ...

Chronic kidney disease is a gradual, irreversible loss of kidney function caused by diabetes, hypertension, or ageing. It ...

A mismatch between two common tests for kidney function may indicate a higher risk for kidney failure, heart disease, and ...

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...

If the drug works in people, it could prevent kidney injury in high-risk populations, or potentially even treat other ...

Researchers have made a major medical breakthrough after they created human kidney organoids and transplanted them into pigs.

A research team led by the Institute for Bioengineering of Catalonia (IBEC) and collaborating with the Biomedical Research ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® ...

The Liberation From Acute Dialysis (LIBERATE-D) randomized clinical trial tested the value of a conservative vs conventional hemodialysis strategy on recovery of kidney function in stable patients ...

A multi‐centre Ghanaian study found that the prevalence of CKD in people with hypertension and/or diabetes was rising; the ...